切换至 "中华医学电子期刊资源库"

中华老年骨科与康复电子杂志 ›› 2020, Vol. 06 ›› Issue (06) : 351 -356. doi: 10.3877/cma.j.issn.2096-0263.2020.06.007

所属专题: 文献

骨质疏松

阿仑磷酸钠对糖尿病骨质疏松症患者骨代谢的影响
杨利1, 李强1, 阚志芸1, 侯海生1,()   
  1. 1. 066000 秦皇岛,河北省秦皇岛军工医院急诊科
  • 收稿日期:2019-12-12 出版日期:2020-12-05
  • 通信作者: 侯海生
  • 基金资助:
    秦皇岛市2019年重点研发计划科技支撑项目(20191365)

Effects on bone metabolism in patients with diabetic osteoporosis using alendronate

Li Yang1, Qiang Li1, Zhiyun Kan1, Haisheng Hou1,()   

  1. 1. Department of Emergency, Hebei Qinhuangdao Military Hospital, Qinhuangdao 066000, China
  • Received:2019-12-12 Published:2020-12-05
  • Corresponding author: Haisheng Hou
  • About author:
    Corresponding author: Hou Haisheng, Email:
引用本文:

杨利, 李强, 阚志芸, 侯海生. 阿仑磷酸钠对糖尿病骨质疏松症患者骨代谢的影响[J/OL]. 中华老年骨科与康复电子杂志, 2020, 06(06): 351-356.

Li Yang, Qiang Li, Zhiyun Kan, Haisheng Hou. Effects on bone metabolism in patients with diabetic osteoporosis using alendronate[J/OL]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2020, 06(06): 351-356.

目的

探究阿仑磷酸钠对糖尿病骨质疏松症(DOP)患者骨代谢的影响。

方法

前瞻性收集2017年12月至2018年12月秦皇岛军工医院收治的108例DOP患者,随机分为对照组(54例)和阿仑磷酸钠组(54例),所有患者均给予常规对症及降糖治疗,阿仑磷酸钠组在此基础上给予阿仑膦酸钠片。治疗2个月后,观察并比较两组患者的骨代谢指标、骨密度(BMD)、血生化指标和临床疗效。

结果

治疗后,对照组的血清骨代谢指标骨特异型碱性磷酸酶(BAP)、骨钙素(BGP)、人抗酒石酸酸性磷酸酶5b(TRAP-5b)水平分别为(7.52±3.20)μg/L、(6.24±2.22)U/L、(3.30±1.13)ng/ml,阿仑磷酸钠组分别为(9.41±3.32)μg/L、(7.73±2.34)U/L、(2.45±1.18)ng/ml;治疗后,两组BAP和BGP水平较治疗前升高(t=4.670,t=6.120,P<0.05),组间比较,阿仑磷酸钠组高于对照组,差异有统计学意义(t=3.010,t=3.390,P<0.01);两组TRAP-5b(t=4.780,t=5.620,P<0.05)水平较治疗前下降,组间比较,阿仑磷酸钠组低于对照组,差异有统计学意义(t=3.820,P<0.01)。治疗后,对照组的腰椎和股骨颈的BMD分别为(0.82±0.06)g/cm2、(0.74±0.05)g/cm2,阿仑磷酸钠组分别为(0.91±0.04)g/cm2、(0.83±0.08)g/cm2,两组腰椎和股骨颈BMD(t=3.840,t=3.760,P<0.05)水平较治疗前均升高,组间比较,阿仑磷酸钠组高于对照组(t分别=9.170和7.010,P<0.05)。治疗后,对照组空腹血糖(FBG)、餐后2 h血糖(2 hBG)、糖化血红蛋白(HbA1c)水平分别为(7.06±0.29)mmol/L、(8.02±3.17)mmol/L、(6.21±0.46)%,对照组FBG、2 hBG、HbA1c水平分别为(8.12±0.33)mmol/L、(9.98±0.54)mmol/L、(7.56±0.67)%,两组比较,阿仑磷酸钠组低于对照组,差异有统计学意义(t=17.730,4.480,12.210,P<0.01)。阿仑磷酸钠组总有效率(90.74%)高于对照组(79.63%,P<0.05)。

结论

阿仑磷酸钠治疗DOP患者疗效显著,可有效改善其骨代谢,促进BMD水平增加,值得临床加以推广与应用。

Objective

To explore the effect on bone metabolism in patients with diabetic osteoporosis (DOP) using alendronate.

Methods

108 patients with DOP hospitalized in our hospital from December 2017 to December 2018 were randomly divided into the control group (54 cases) and the alendronate group (54 cases). All patients were treated with routine treatment and alendronate group was given alendronate tablets on this basis. After 2 months treatment, the bone metabolism index, bone mineral density (BMD), blood biochemical index and clinical efficacy were observed and compared between the two groups.

Results

After treatment, the serum bone metabolism indexes bone specific alkaline phosphatase (BAP), osteocalcin (BGP) and human tartrate-resistant acid phosphatase 5b (TRAP-5b) in the control group were (7.52±3.20) μg/L, (6.24±2.22) U/L, (3.30±1.13) ng/ml, respectively, and the alendronate group was (9.41±3.32) μg/L, (7.73±2.34) U/L, (2.45±1.18) ng/ml, respectively. After treatment, the levels of BAP (t=4.670, P<0.05) and BGP (t=6.120, P<0.05) in the two groups were higher than those before treatment. Compared with the control group, the levels of sodium alendronate group were significantly higher than those in the control group, with statistically significant differences (t=3.010 and 3.390, P<0.01, respectively). Trap-5b (t= 4.780 and 5.620, P<0.05, respectively) level of the two groups decreased compared with that before treatment. Compared with the control group, sodium alendronate group was significantly lower than the control group, and the difference was statistically significant (t=3.820, P<0.01). There was no significant difference in bone metabolism before and after treatment in the control group (P>0.05). After treatment, the BMD of lumbar spine and femoral neck in the control group were (0.82±0.06) g/cm2 and (0.74±0.05) g/cm2, respectively, and those in the alenphosphate group were (0.91±0.04) g/cm2 and (0.83±0.08) g/cm2, respectively. BMD levels in lumbar spine and femoral neck (t=3.840 and 3.760, P<0.05, respectively) were higher in both groups than before treatment, and the alendronate group was higher than the control group (t=9.170 and 7.010, P<0.05, respectively). After treatment, fasting blood glucose (FBG), postprandial blood glucose (2 hBG), glycadified hemoglobin (HbA1c) levels in the control group were (7.06±0.29) mmol/L, (8.02±3.17) mmol/L, (6.21±0.46)%, respectively. The FBG, 2 hBG, and HbA1c levels in the control group were (8.12±0.33) mmol/L, (9.98±0.54) mmol/L, and (7.56±0.67)%, respectively. The comparison between the two groups showed that the alenophosphate group was significantly lower than the control group, with statistically significant differences (t=17.730, 4.480, 12.210, P<0.01). The total effective rate was 90.74% significantly higher than 79.63% in the control group (P<0.05).

Conclusion

Alendronate combined with control was effective in the treatment of patients with DOP, and it can improve bone metabolism and increase the level of BMD, which was worthy of clinical promotion and application.

表1 两组糖尿病骨质疏松症患者一般资料
表2 两组糖尿病骨质疏松症患者治疗前后骨代谢相关指标的比较(±s
表3 两组DOP患者治疗前后相关部位BMD值的比较(g/cm2±s
表4 两组DOP患者治疗后2个月血生化指标比较(±s
表5 两组DOP患者临床疗效比较[例(%)]
1
Yoo TK, Kim SH, Kwak J, et al. Association between osteoporosis and Age-Related macular degeneration: the Korea National health and nutrition examination survey [J]. Invest Ophthalmol Vis Sci, 2018, 59(4): AMD132-AMD142.
2
Lei C, Xueming H, Ruihang D. MLN64 deletion suppresses RANKL-induced osteoclastic differentiation and attenuates diabetic osteoporosis in streptozotocin (STZ)-induced mice [J]. Biochem Biophys Res Commun, 2018, 505(4): 1228-1235.
3
刘丹丹,常虹,谈敏.男性2型糖尿病患者25羟维生素D3及骨代谢指标的变化分析[J].安徽医药,2015,19(2): 288-291.
4
蔡德,林志绣,黄志华,等.阿仑磷酸钠联合金天格胶囊治疗绝经后骨质疏松临床观察[J].中国药师,2015,18(8): 1352-1354.
5
姚新苗,史晓林,王健,等.浙江省中医药防治原发性骨质疏松症分级诊疗专家共识(2017)[J].浙江中医杂志,2018,53(4): 237-241.
6
廖涌.中国糖尿病的流行病学现状及展望[J].重庆医科大学学报,2015,40(7): 1042-1045.
7
郑博,蒋涛,黄佳涌,等.我国中老年脆性髋部骨折及桡骨远端骨折骨质疏松诊断标准与WHO诊断标准的比较分析[J].中国骨质疏松杂志,2018,24(10): 1299-1304.
8
赵彦杰,何兰杰.2型糖尿病骨质疏松、胰岛素抵抗与维生素D水平的相关性[J].宁夏医学杂志,2015,37(3): 256-258.
9
刘爽,杨梅.糖尿病骨质疏松症发病机制探讨[J].实用糖尿病杂志,2014,10(6): 59-60.
10
王芳,任汉强,沈晓波.胰岛素联合阿仑膦酸钠对老年糖尿病骨质疏松症患者骨密度及血清BAP、TRAP-5b、BGP水平影响[J].海南医学院学报,2016,22(13): 1387-1389+1393.
11
陈华.阿仑膦酸钠联合碳酸钙D_3片治疗2型糖尿病性骨质疏松症疗效观察[J].药物流行病学杂志,2015,24(8): 451-453+459.
12
王玉容,方向明,叶文春,等.唑来膦酸注射液治疗糖尿病骨质疏松患者的疗效研究[J].四川医学,2015,36(1): 69-71.
13
陈玉凤,郭献山,赵建林,等.老年2型糖尿病中性粒细胞/淋巴细胞比率与骨质疏松症的关系[J].中国骨质疏松杂志,2015,21(7): 824-826.
14
Fuglsang-Nielsen R, Starup-Linde J, Gregersen S, et al. The effect of meals on bone turnover - a systematic review with focus on diabetic bone disease [J]. Expert Rev Endocrinol Metab, 2018, 13(5):233-249.
15
丛宝华,赵方,宋飞,等.胰岛素联合阿仑膦酸钠对2型糖尿病骨质疏松症患者骨代谢的影响[J].现代生物医学进展,2017,17(3): 516-519.
16
屈强,蔺改雯,金晶.阿仑磷酸钠与阿法骨化醇胶丸联合用药治疗绝经后骨质疏松症疗效观察[J].陕西医学杂志,2015,44(7): 906-908.
17
朱超,刘伟,王华,等.阿仑磷酸钠联合阿法骨化醇治疗老年肱骨近端骨折的效果[J].中国医药导报,2016,13(24): 85-88+104.
18
张志梅,张倩辉,李彩英,等.利拉鲁肽联合胰岛素治疗2型糖尿病骨质疏松的疗效[J].西北药学杂志,2018,33(6): 830-833.
19
王兵,杨勋能.2型糖尿病合并骨质疏松患者DEXA骨密度测量结果与血清细胞因子、胰岛素抵抗的关系[J].海南医学院学报,2017,23(2): 277-280.
20
刘君英,阎德文,邓建新,等.围绝经期2型糖尿病骨质疏松症治疗中胰岛素与阿仑膦酸钠的联合应用效果观察[J].山东医药,2017,57(19): 69-71.
21
周庆胜.骨化三醇联合阿仑磷酸钠治疗绝经后骨质疏松症的疗效研究[J].实用妇科内分泌杂志:电子版,2017,4(20): 109+111.
22
赵春芝,娄方勇.胰岛素、阿仑膦酸钠治疗新诊断老年糖尿病骨质疏松症患者骨密度及骨转换指标的研究[J].中国骨质疏松杂志,2014,20(4): 392-395,438.
[1] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[2] 蚁淳, 袁冬生, 熊学军. 系统免疫炎症指数与骨密度降低和骨质疏松的关联[J/OL]. 中华关节外科杂志(电子版), 2024, 18(05): 609-617.
[3] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[4] 徐志刚, 曹涛, 何亭, 李博奥, 魏婧韬, 张栋梁, 官浩, 杨薛康. 采用抗生素骨水泥治疗糖尿病患者心脏术后胸骨骨髓炎的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 498-502.
[5] 姜珊, 李湘燕, 田硕涵, 温冰, 何睿, 齐心. 采用优化抗感染治疗模式改善糖尿病足感染预后的临床观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 398-403.
[6] 别瑶, 曹志斌, 辛静, 王健楠, 惠宗光. 应用基质血管成分细胞治疗糖尿病足溃疡的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 453-456.
[7] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[8] 李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[9] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[10] 周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[11] 杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[12] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[13] 王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.
[14] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
[15] 李玺, 蔡芸莹, 张永红, 苏恒. 假性软骨发育不全合并1型糖尿病一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 518-520.
阅读次数
全文


摘要